Zai Lab And Innoviva Specialty Therapeutics Receives NMPA Approval For XACDURO (Sulbactam-Durlobactam) For Hospital-Acquired And Ventilator-Associated Pneumonia Caused By Acinetobacter Baumannii-Calcoaceticus Complex In China
Portfolio Pulse from Benzinga Newsdesk
Zai Lab and Innoviva Specialty Therapeutics have received approval from China's NMPA for XACDURO (Sulbactam-Durlobactam) to treat hospital-acquired and ventilator-associated pneumonia caused by Acinetobacter baumannii-calcoaceticus complex. This approval is based on clinical data showing strong activity against carbapenem-resistant strains.
May 20, 2024 | 4:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Innoviva Specialty Therapeutics received NMPA approval for XACDURO in China, targeting a significant health threat with robust clinical data.
The approval of XACDURO by China's NMPA is a significant milestone for Innoviva, as it addresses a major health threat with a high prevalence of drug-resistant infections. This could lead to increased revenue and market presence in China.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Zai Lab received NMPA approval for XACDURO in China, targeting a significant health threat with robust clinical data.
The approval of XACDURO by China's NMPA is a significant milestone for Zai Lab, as it addresses a major health threat with a high prevalence of drug-resistant infections. This could lead to increased revenue and market presence in China.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100